Reports Q4 revenue $7.162M, consensus $5.35M. "2022 was a year of significant growth and execution for Marinus, underscored by the successful U.S. launch of ZTALMY," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "With a strong balance sheet and continued progress advancing our second generation formulation and Phase 3 trials in status epilepticus and tuberous sclerosis complex, we entered 2023 with increased confidence in our ability to expand the value proposition of ganaxolone in rare epilepsies."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRNS:
- Marinus Pharmaceuticals options imply 12.7% move in share price post-earnings
- Billionaire Steve Cohen Pulls the Trigger on These 2 ‘Strong Buy’ Stocks
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Marinus Pharmaceuticals initiated with an Outperform at RBC Capital
- Marinus Pharmaceuticals management to meet with Cantor Fitzgerald
